RealTime Dynamix™: Atopic Dermatitis US Q3

Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash. Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. [...]

RealTime Dynamix™: Atopic Dermatitis US Q3 2017-08-16T13:23:30+00:00

RealWorld Dynamix™: Biologic/JAK Switching in RA US 2017

There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA) in the United States. With the more established TNF-inhibiting biologics on the market for nearly two decades, RA treatment protocol and payer policy tend to dictate their use as first-line biologics. However, rheumatologists [...]

RealWorld Dynamix™: Biologic/JAK Switching in RA US 2017 2017-08-10T18:37:54+00:00

RealTime Dynamix™: Inflammatory Bowel Disorder US Q3

Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), and Crohn’s Disease (CD) currently affects the lives of approximately 1.6 million Americans. The use of biologics has changed the face of treatment for moderate-to-severe IBD patients. However, recent launches, an active pipeline, and the introduction of biosimilars present an opportunity for major future shifts in the IBD [...]

RealTime Dynamix™: Inflammatory Bowel Disorder US Q3 2017-08-29T18:59:57+00:00

RealWorld Dynamix™: Dialysus US 2017

The management of renal anemia in dialysis patients as well as in those with later stage chronic kidney disease is becoming increasingly complex. In the dialysis setting, clinical management is further complicated by a reimbursement model that treats commonly used therapies like erythropoiesis stimulating agents (ESAs) and iron therapies as cost centers. Novel products in [...]

RealWorld Dynamix™: Dialysus US 2017 2017-08-10T18:47:08+00:00

RealTime Dynamix™: Ankylosing Spondylitis & Non-radiographic Axial Spondyloarthritis US Q2

Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis (AS). The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). In nr-axSpA, the impact on quality of life is rated as high, [...]

RealTime Dynamix™: Ankylosing Spondylitis & Non-radiographic Axial Spondyloarthritis US Q2 2017-08-10T18:39:34+00:00